Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The IL-8/NF-κB feedback loop confers a paclitaxel-sensitive/doxorubicin-resistant phenotype in triple-negative breast cancer

1 Jul 2025

Abstract excerpt

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is highly metastatic compared with other BC subtypes. Taxane- and anthracycline-based therapies remain the main clinical TNBC regimens. However, TNBC patients usually suffer through chemotherapy owing to the lack of valid biomarkers to predict therapeutic effectiveness. We found that IL-8 upregulation is detected in paclitaxel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40582426
DOI: 10.1016/j.freeradbiomed.2025.06.049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The IL-8/NF-κB feedback loop confers a paclitaxel-sensitive/doxorubicin-resistant phenotype in triple-negative breast cancerPMID 40582426Read ↗

A Comprehensive Immunologic Portrait of Triple-Negative Breast CancerSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Inflammation-associated drug resistance and tumor growth in TNBCSemantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Development of a Prognostic Model Based on Identification of EMT-related LncRNAs in Triple Negative Breast CancerSemantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activitySemantic proximity Read ↗

Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast CancerSemantic proximity Read ↗

TNFRSF12A Drives Triple-Negative Breast Cancer Progression via Immune Microenvironment Reprogramming and Facilitated AngiogenesisSemantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.